Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia

Reata Submitted New Data and Analyses to Address FDA Questions During Mid-Cycle Meeting

FDA Extended PDUFA Date to Provide Time for Full Review of New Submissions

PDUFA Date Extended to February 28, 2023

PLANO, Texas--(BUSINESS WIRE)-- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, announced that on August 8, 2022, after the U.S. financial markets closed, we received a communication from the U.S. Food and Drug Administration (“FDA”) informing us that they have extended the review timeline for the New Drug Application (“NDA”) for omaveloxolone for the treatment of Friedreich’s ataxia by three months.

Read the Full article here
 


SHARE
 

Scientific News Archives

Tagged in
Scientific News

Beaker

Privacy Policy      Service Terms      Contact      Charity Navigator